Botensilimab by Agenus for Ovarian Cancer: Likelihood of Approval

Botensilimab is under clinical development by Agenus and currently in Phase I for Ovarian Cancer.

Related Keywords

Massachusetts ,United States , ,Globaldata Pharmaceutical Intelligence Center ,Ovarian Cancer ,Phase Transition Success Rate Model ,Heat Shock Protein ,Pharmaceutical Intelligence ,